Navigation Links
Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
Date:7/1/2008

HELSINKI, July 1 /PRNewswire/ -- The emergence of multidrug-resistant Gram-negative bacteria has necessitated the use of polymyxins as the agents of last resort despite their known nephrotoxicity. Now Northern Antibiotics Ltd, a Finnish biotech company, has developed novel polymyxin derivatives which in early preclinical studies show signs of lower nephrotoxicity.

The derivatives contain three positive charges only, while polymyxin B and colistin have five. They bind to the isolated brush-border membrane of rat kidney at an affinity which is only 1/5-1/7 of that for polymyxin B. In vivo rat studies also show remarkable differences in parameters that are considered to indicate early kidney damage, such as serum urea nitrogen, albuminuria and cylindrouria.

The derivatives fall in to two groups that differ in their mode of action. The lead compound of the first group, NAB 7061, sensitizes enteric bacteria to other antibiotics. For example, it reduces the minimum inhibitory concentration (MIC) of clarithromycin for ESBL-producing strains of Escherichia coli by a factor of 250-750. NAB 739, the lead compound of the second series, acts directly against enteric bacteria. For E. coli (including ESBL-producing strains) the MIC90 is identical to that of polymyxin B. While NAB 739 is already alone highly active against multidrug-resistant strains of Acinetobacter baumannii, it also at very low subinhibitory concentrations sensitizes this bacterium to other antibiotics. A paper entitled "Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents" was published ahead of print on June 30, 2008 (Antimicrob. Agents Chemother., doi:10.1128/AAC.00405-08).

"The efficacy of both lead compounds has been verified using an experimental E. coli peritonitis model in mice, and we are now talking to potential partners to further develop and eventually commercialize these two lines of novel compounds," says Professor Martti Vaara, CEO and co-founder of Northern Antibiotics Ltd.

"The need for well-tolerated antibiotics that are active against multidrug-resistant Gram-negative bacteria is urgent. Enteric bacteria are responsible for more than 80% of all the hospital infections caused by Gram-negative bacteria, and now they are rapidly becoming resistant to most antibiotics that are currently used to treat them. Plasmid-mediated carbapenemases, probably transferred from Klebsiella pneumoniae, have now been found in E. coli, the clinically most important species of Gram-negative enteric bacteria. Also plasmid-mediated methylases that cause resistance to all aminoglycosides have been encountered. Finally and quite alarmingly, a single genetic element conferring transferable resistance to carbapenems, aminoglycosides and fluoroquinolones has been reported in K. pneumoniae. One does not need to be very smart to guess what follows when these plasmids become more common and the resulting extremely multidrug-resistant strains start to spread."

About Northern Antibiotics Ltd.

Founded in 2003 and headquartered in Helsinki, Finland, Northern Antibiotics Ltd is engaged in the discovery and development of novel antibiotics against multidrug-resistant Gram-negative bacteria. For more information, visit http://www.northernantibiotics.com.

Contact:

Dr. Barry Mason

Business Development Consultant

Email: barry.mason@northernantibiotics.com

Phone: +44(0)1625-858396

Mobile: +44(0)7713-261356


'/>"/>
SOURCE Northern Antibiotics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
2. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
3. For Most, Good Oral Care Does More Than Antibiotics to Prevent Dental-Related Heart Problems, Reports the Harvard Heart Letter
4. Nventa Develops Proprietary Vaccine Adjuvant
5. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
6. DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin
7. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
8. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
9. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
10. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
11. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
Breaking Medicine Technology:
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):